News & Updates

Women who regularly consume dairy products do not have an increased risk of developing breast cancer, reveals a study. However, there is heterogeneity seen for the type of dairy food, period of life, and tumour subtypes.

Palliative-intent radiation was performed more frequently in patients with advanced nonsmall-cell lung cancer (NSCLC) and cachexia than those without weight loss. Unfortunately, tumour-directed therapy, whether in a curative or a palliative approach, proves inadequate in improving cachexia patient survival across all stages of the disease.

Treatment with sitravatinib plus nivolumab (sitra + nivo) results in numerically longer median overall survival (OS), albeit statistically nonsignificant, in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC) compared with docetaxel, a study has shown.

Third-line treatment with sacituzumab govitecan works better than the physician’s treatment of choice in metastatic triple-negative breast cancer (mTNBC), an invasive histologic subtype with a poor prognosis and rapid progression, as shown in a recent study.

Recurrence-free survival (RFS) is significantly longer with erdafitinib treatment than with intravesical chemotherapy in patients with papillary-only, high-risk nonmuscle-invasive bladder cancer (NMIBC) who had disease recurrence after bacillus Calmette–Guérin (BCG) therapy and were ineligible for radical cystectomy, according to a study.

Amivantamab plus chemotherapy with or without lazertinib results in longer progression-free survival (PFS), as well as intracranial PFS, compared with chemotherapy alone in patients with epidermal growth factor receptor (EGFR)-mutated advanced nonsmall-cell lung cancer (NSCLC) who had disease progression on or after osimertinib, results of the phase III MARIPOSA-2 study have shown.

The addition of internal mammary nodal irradiation (IMNI) in the treatment of breast cancer leads to better overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and lower breast cancer mortality (BCM), reveals a study. In addition, patients with pN+ and medial/central tumour location achieved the best OS from IMNI.